Sandoz Group AG | Finanzwire

Basculer en Français

9705	Companies
193533	Keywords
124776	Articles
103022	Press releases

Home
Companies
Sandoz Group AG

BRIEF

published on 11/17/2025 at 07:05, 2 months 3 days ago

Sandoz Launches First MS Biosimilar TYRUKO® in US

Multiple Sclerosis Biosimilar Sandoz TYRUKO® Natalizumab
PRESS RELEASE

published on 11/17/2025 at 07:00, 2 months 3 days ago

Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Sandoz launches TYRUKO® (natalizumab-sztn) in US, the first and only multiple sclerosis biosimilar, offering cost-effective treatment. TYRUKO® approved for all indications of reference medicine Tysabri®

US Market Multiple Sclerosis Biosimilar Sandoz TYRUKO
BRIEF

published on 11/12/2025 at 07:40, 2 months 8 days ago

Sandoz Secures Global License for Breast Cancer Biosimilar

Oncology Biosimilar Breast Cancer Sandoz Pertuzumab
PRESS RELEASE

published on 11/12/2025 at 07:35, 2 months 8 days ago

Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
Sandoz signs global license agreement with EirGenix Inc. to commercialize biosimilar pertuzumab for HER2-positive breast cancer treatment, reinforcing its position in oncology

Agreement Biosimilar Breast Cancer Sandoz Pertuzumab
BRIEF

published on 11/04/2025 at 22:10, 2 months 16 days ago

Sandoz Acquires Just-Evotec Biologics to Expand Biosimilars Capabilities

Acquisition Biosimilars Toulouse Sandoz Just-Evotec
PRESS RELEASE

published on 11/04/2025 at 22:05, 2 months 16 days ago

Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
Sandoz strengthens biosimilars capabilities with acquisition of Just-Evotec Biologics EU SAS in Toulouse. Acquisition aims to capture projected biosimilar market opportunity. Transaction includes cash payment and technology license fees

Acquisition Biosimilars Sandoz Just-Evotec Biologics Continuous Manufacturing Technology
BRIEF

published on 10/30/2025 at 07:05, 2 months 21 days ago

Sandoz Reports Growth in Sales and Upgraded Margin Guidance

Financial Guidance Sales Growth Biosimilars Regional Performance Trade Issues
PRESS RELEASE

published on 10/30/2025 at 07:00, 2 months 21 days ago

Sandoz delivers a further acceleration in sales growth; full-year margin guidance upgraded
Sandoz reports 5% growth in net sales for 9 months, with biosimilars contributing over 30%. Full-year margin guidance raised to 21-22% core EBITDA

EBITDA Net Sales Biosimilars Sandoz Margin Guidance
BRIEF

published on 09/09/2025 at 07:05, 4 months 11 days ago

Sandoz and Regeneron Resolve Patent Dispute

FDA Approval Biosimilar Sandoz Regeneron Aflibercept
PRESS RELEASE

published on 09/09/2025 at 07:00, 4 months 11 days ago

Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar
Sandoz reaches agreement with Regeneron on patent litigation related to US aflibercept biosimilar, enabling launch of Enzeevu™ by end of 2026. Agreement strengthens Sandoz biosimilar portfolio and expands US market growth strategy

Biosimilar Patent Litigation Sandoz Regeneron Enzeevu

Accesswire

Published on 01/21/2026 at 00:30, 54 minutes ago

Caledonia Announces Closing of Upsized $150 Million Convertible Senior Notes Offering and Full Exercise of Initial Purchasers' Option to Purchase Additional Notes
Published on 01/20/2026 at 23:35, 1 hour 49 minutes ago

Further Shallow High-Grade Assays Infill Tunkillia S1/2 Pits
Published on 01/20/2026 at 23:30, 1 hour 54 minutes ago

Correction to Press Release Issued on January 16, 2026 Announcing Closing of $976,000 Non-Brokered Private Placement
Published on 01/20/2026 at 23:20, 2 hours 4 minutes ago

Pathfinder Ventures Announces $2 Million Non-Brokered Private Placement
Published on 01/20/2026 at 23:00, 2 hours 24 minutes ago

Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Due Diligence Review

View all ACCESSWIRE

EQS Group

Published on 01/21/2026 at 00:50, 34 minutes ago

T.D. Williamson launches SHiiELD™ double independent isolation and bleed system
Published on 01/20/2026 at 20:00, 5 hours 24 minutes ago

Purchase of all outstanding Bell Group N.V. notes CH0005575151, GB0040901711 and XS0000001247
Published on 01/20/2026 at 19:19, 6 hours 4 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares – conclusion and extension of buyback programme
Published on 01/20/2026 at 18:05, 7 hours 19 minutes ago

PRC-Saltillo Announces Acquisition of Therapy Box® Apps, Enhancing AAC Communication Options Worldwide
Published on 01/20/2026 at 16:15, 9 hours 9 minutes ago

Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy

Les Echos

Published on 01/20/2026 at 17:59, 7 hours 24 minutes ago

Statement of transactions in own shares from January 14, 2026 to January 16, 2026
Published on 01/20/2026 at 17:45, 7 hours 39 minutes ago

Change in Baikowski® executive management
Published on 01/20/2026 at 07:30, 17 hours 54 minutes ago

Gimv leads € 51 million Series B investment round in Exciva to advance innovative Alzheimer’s therapy
Published on 01/19/2026 at 17:45, 1 day 7 hours ago

Financial communication calendar 2026
Published on 01/19/2026 at 17:35, 1 day 7 hours ago

EURAZEO ENTERS INTO AN EXCLUSIVE AGREEMENT WITH L CATTERTON FOR THE SALE OF ITS MINORITY STAKE IN EX NIHILO

View all LES ECHOS COMFI WIRE